Study #2023-0335
A phase 3 randomized, open-label, multicenter study of Zanubrutinib (BGB-3111) plus anti-CD20 antibodies versus Lenalidomide Plus Rituximab in patients with Relapsed/Refractory follicular or marginal zone lymphoma
MD Anderson Study Status
Enrolling
Treatment Agent
Zanubrutinib, Obinutuzumab, Rituximab, Lenalidomide
Description
The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R\^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free survival as determined by an independent review committee in accordance with the 2014 modification of the International Working Group on non-Hodgkin lymphoma (NHL) Criteria based on n positron emission tomography and computed tomography (PET/CT), and to compare the efficacy of zanubrutinib plus rituximab versus R\^2 in participants with R/R marginal zone lymphoma (MZL), as measured by progression free survival (PFS) assessed by IRC in accordance with CT-based Lugano 2014 Criteria.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma
Study phase:
Phase III
Physician name:
Chijioke Nze
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.